Iqvia
Provides information, services and technology for the healthcare industry.
Based in CT
🤖
AI Overview
With $880K in lobbying spend across 18 quarterly filings, Iqvia is an active lobbying client. Their lobbying covers 6 issue areas. Active from 2021 to 2025.
$880K
Total Spend
5
Years Active
1
Firms Hired
9
Lobbyists Deployed
6
Issues Lobbied
Spending Trend
View as table
| Year | Lobbying Spend |
|---|---|
| 2021 | $30K |
| 2022 | $200K |
| 2023 | $210K |
| 2024 | $200K |
| 2025 | $240K |
Issues Lobbied
Lobbying Firms
Lobbyists
What They Lobby About
These are actual descriptions from their quarterly lobbying disclosure filings, summarizing what they lobbied Congress and federal agencies about.Issue areas: Budget/Appropriations, Science/Technology, Health Issues, Pharmacy, Defense and 1 more
- •Monitor COVID relief issues. Appropriations.
- •Appropriations.
- •Monitor COVID relief issues.
- •Issues related to health data policy and clinical trials. Issues related to secure healthcare mobile applications for the military.
Related Analysis
📈 Client Trajectories
See how this client compares to others over time
🎯 Market Concentration
How concentrated is the lobbying market?
🚀 Spending Momentum
Which issues are surging right now?
🏭 Tech Lobbying
Industry overview and top spenders
🏭 Pharma Lobbying
Industry overview and top spenders
🏭 Defense Lobbying
Industry overview and top spenders
Related Investigations
The 22,000% ROI
When lobbying spending yields outsized returns.
Big Tech's $150M Lobbying War
Tech giants battle over AI, antitrust, privacy, and trade.
Big Pharma's $452M Lobbying Machine
How pharmaceutical companies spend hundreds of millions to influence health policy.
Healthcare's $3 Billion Bet
The healthcare industry's massive lobbying investment.
The Defense Lobby
Defense contractors spend millions lobbying for contracts worth billions.
Lobbying vs. Federal Contracts
How lobbying spending correlates with contract awards.
Similar Clients
Explore More
Data Sources: Senate LDA Filings
Last updated: February 2026
This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.